Newly Diagnosed?
Finding out you’re sensitized can be overwhelming. The good news is that with the right care and close monitoring, most babies do really well. HDFN can be complex, and many families find themselves having to advocate for both themselves and their baby, from choosing the right care team to ensuring proper monitoring during pregnancy and follow-up after birth.
Connect With a Family
Sometimes it helps to talk to someone who’s been through it. We can connect you with another family who’s faced a similar diagnosis. Whether you have questions or just want to hear what it was like for someone else, we’re here to make that connection.
MAF Support Group
This is a safe, private space for women who have been diagnosed with maternal red blood cell antibodies—whether you’re newly diagnosed, trying to conceive, currently pregnant, or have recently delivered a baby affected by HDFN.
The Azalea Trial
Azalea, a clinical research study for women with pregnancies at risk for severe HDFN is currently enrolling. The purpose of the study is to assess the safety and efficacy of an investigational medication in pregnancies at risk for severe HDFN. Interested in participating?
What is HDFN
Hemolytic Disease of the Fetus and Newborn (HDFN) is a condition that occurs when a pregnant woman’s immune system produces antibodies that attack and destroy the baby’s red blood cells.
Understanding Alloimmunization & HDFN
History
The first known case of what we now call HDFN was recorded in 1609 by a French midwife who delivered twins. One baby was born severely swollen and passed away shortly after birth, while the other developed jaundice and died a few days later. For centuries, similar heartbreaking cases were reported, but the cause remained a mystery.
It wasn’t until the 1950s that doctors discovered HDFN occurs when a baby’s red blood cells are attacked by antibodies from the mother. This usually happens when the mother’s blood type is not compatible with the baby’s, causing her immune system to see the baby’s cells as foreign.
HDFN most commonly affected babies with Rh-positive blood born to Rh-negative mothers, but it can also occur due to other types of alloantibodies, such as anti-Kell, anti-c In the 1960s, the development of Rho(D) immune globulin (RhoGAM) changed everything. This medication, given during and after pregnancy, helps prevent Rh-negative mothers from becoming sensitized and dramatically reduced the number of babies affected by Rh-related HDFN.
Today, thanks to medical advances such as early antibody screening, close monitoring, and treatments like intrauterine transfusions and phototherapy, most babies affected by HDFN go on to do very well with proper care.
Causes
HDFN happens when a baby’s red blood cells are different from the mother’s, and the mother’s immune system sees them as foreign. In response, her body creates antibodies that can cross the placenta and begin breaking down the baby’s red blood cells, which can lead to anemia, jaundice, or more serious complications.
This usually happens because of a difference in blood type or certain red blood cell traits called antigens. The most common cause is Rh incompatibility, which occurs when a mother is Rh-negative and her baby is Rh-positive. However, HDFN can also be caused by other antibodies such as anti-Kell, anti-c, anti-E, and others. These are known as red cell alloantibodies.
Often, these antibodies form during a previous pregnancy, miscarriage, or blood transfusion, and they stay in the mother’s body long-term. In a future pregnancy, those same antibodies can react more quickly and strongly if the baby has the matching antigen. That is why early blood testing, close monitoring, and planning with specialists are so important for families facing maternal alloimmunization.
Diagnosis
Early in prenatal care, most patients get a routine blood test called an antibody screen (also known as an indirect Coombs test), which is included as part of a type and screen. This test checks your blood type, Rh factor, and whether your immune system has made any red blood cell antibodies that could harm the baby. If antibodies are found, doctors will measure the level—called a titer—and monitor it closely to see if it changes.
Significant Antibodies
Many antibodies can cause HDFN. These include, but are not limited to:Anti-D (the most well-known, linked to Rh incompatibility), Anti-C, Anti-c, Anti-E, Anti-e, Anti-K (Kell), Anti-Fya, Anti-Fyb, Anti-Jka, Anti-Jkb, Anti-M, Anti-S, Anti-s, Anti-Jsa, Anti-Dia, Anti-Wra, Anti-Lua, Anti-Lub, Anti-Cw, Anti-Kpa, and Anti-Vel.
RH Incompatibility & RhoGam
Rh incompatibility was once the most common cause of alloimmunization and HDFN. It occurs when a mother has Rh-negative blood and her baby has Rh-positive blood, inherited from the father. If the mother and baby’s blood mix during pregnancy or delivery, the mom’s body may produce antibodies which can affect future pregnancies.
To prevent this, Rh-negative mothers are typically given an injection called Rho(D) immune globulin, or RhoGAM, around 28 weeks of pregnancy and again after delivery if the baby is confirmed to be Rh-positive. RhoGAM works by clearing any Rh-positive cells from the mother’s bloodstream before her immune system has a chance to react to them.
Thanks to RhoGAM, Rh-related HDFN is now much less common. However, it’s important to know that RhoGAM only works as prevention. Once a mother has formed alloantibodies, RhoGAM will no longer be effective, and close monitoring and care are needed in future pregnancies.
How Do I Know If My Baby Is at Risk?
If there’s a known risk, doctors may recommend testing the baby’s father to see if he carries the red cell trait (or antigen) targeted by the mother’s antibodies. If he has two copies of the antigen, the baby is certain to inherit it. If he has only one copy, or if paternity is uncertain, a non-invasive test called cell-free DNA (cffDNA) can be done starting at 10 weeks. This test analyzes tiny fragments of the baby’s DNA found in the mother’s blood to determine whether the baby inherited the antigen. These results help your care team assess the baby’s risk and decide how closely the pregnancy needs to be monitored.
Monitoring During Pregnancy
As pregnancy progresses, if the baby is thought to be at risk based on the mother’s antibody levels (titer) and the baby’s antigen status, doctors use a special kind of ultrasound called an MCA Doppler to measure blood flow in the baby’s brain. This test helps detect early signs of anemia and is completely safe and non-invasive. It usually begins around 18 to 20 weeks and may be repeated every one to two weeks, depending on the situation.
Diagnosis After Birth
After the baby is born, doctors check for HDFN by testing the baby’s cord blood. They look at the baby’s blood type, hemoglobin level, bilirubin level, and do a test called the direct Coombs test (DAT). If the DAT is positive, it means the mother’s antibodies have attached to the baby’s red blood cells. This can cause the baby to become anemic or develop jaundice (yellowing of the skin and eyes). Even if the DAT is negative, some babies still need close monitoring, ESPECIALLY if they received a transfusion before birth(IUT) or if symptoms appear later.
Care Guidelines & Support
Featured Resources
Knowledge is powerful, especially when it comes to your baby’s health. These featured tools, articles, and handouts are here to help you feel informed, confident, and supported every step of the way.
Common Terms During an Alloimmunized Pregnancy
NST means non stress test- that’s when they put you on the monitors and watch baby’s heart rate and your contractions. Some countries call this a CTG.
HDFN Birth and Infancy Guide
This comprehensive guide provides essential information for parents navigating care after delivery when their baby has been diagnosed with Hemolytic Disease of the Fetus and Newborn (HDFN).
Breaking the Silence on Pregnancy Loss
In this powerful and emotional talk, Cassandra Blomberg combines her personal journey through pregnancy loss with research on miscarriage and stillbirth to explain why we need to break the silence surrounding this topic.
Frequently Asked Questions
Anemia means your baby doesn’t have enough healthy red blood cells to carry oxygen through
their body. In babies affected by HDFN, this happens when maternal antibodies attack and
destroy their red blood cells faster than they can be replaced.
Pale skin, fast breathing or heart rate, difficulty feeding sleepiness or low energy.
Not always. The level of risk depends on the specific antibody and titers, as well as the baby’s antigen status. Many babies are completely unaffected, but some need close monitoring, early intervention, or treatment before or after birth.
You may need:
● Antibody titers (to measure antibody levels)
● Paternal or fetal antigen testing (to see if baby is at risk)
● MCA Doppler ultrasounds (to monitor for fetal anemia)
● Possibly amniocentesis or fetal DNA testing in your blood
Your MFM (high-risk OB) will guide your care based on your specific case.
An MCA Doppler is a special ultrasound that checks how fast blood is flowing through your baby’s brain. If the flow is too fast, it can be a sign of anemia. It’s painless and noninvasive, and often the best tool for deciding if and when treatment is needed.
If your baby becomes anemic in utero, you may need one or more intrauterine transfusions (IUTs), a procedure where blood is given directly to your baby before birth. This is done by specialists and can save your baby’s life.
Yes, many parents still deliver vaginally, but it depends on how the pregnancy progresses. If
your baby has had intrauterine transfusions, or there are concerns about anemia at delivery,
your care team may recommend a planned induction at 37 weeks.
Babies affected by HDFN are usually monitored closely after birth. Some may need:
● Phototherapy for jaundice
● Blood tests for anemia and bilirubin
● Transfusions if anemia is severe
● IVIG or exchange transfusion in more serious cases
Most babies go home after a NICU stay and continue to be followed for several weeks or
months.
Yes! Breastfeeding is safe and encouraged if your baby is stable.
Yes. Many parents go on to have healthy pregnancies after an alloimmunized one, though they are usually monitored more closely from the start. Connecting with a specialist familiar with HDFN is key.
Your partner can have a blood test called antigen typing or zygosity testing, depending on which antibody you’ve tested positive for. This test checks whether your partner carries the antigen that your antibodies are targeting, and whether they have one copy (heterozygous) or two copies (homozygous).
If they are homozygous, the baby will definitely inherit the antigen and will be monitored closely for signs of HDFN. If they are heterozygous, there’s a 50% chance the baby inherited the antigen. This information helps your care team decide whether further testing or extra monitoring is needed during pregnancy.
An intrauterine transfusion (IUT) is a procedure that gives your baby healthy red blood cells
while still in the womb. It’s used to treat severe anemia caused by HDFN and is performed by a
specialist, usually a maternal-fetal medicine (MFM) doctor, in a hospital setting.
You’ll receive numbing medicine on your belly, and sometimes light sedation. Using ultrasound
to guide the way, the doctor places a thin needle through your abdomen and into the umbilical
cord or the baby’s belly to deliver the blood. The procedure usually takes about 30 to 60
minutes. Most patients go home the same day, though you’ll be monitored closely afterward.
Many babies need more than one IUT, especially if the pregnancy is still early. After birth, all
babies who’ve had IUTs need close follow-up care. This includes weekly blood tests for at least
the first 6 weeks, and in many cases, babies are not completely cleared of anemia until 3 or 4
months old.
If you’ve tested positive for red cell antibodies, your care team will closely monitor both you and
your baby throughout pregnancy. Common tests include:
● Antibody screen and titer levels – Regular blood tests to check the strength of your
antibodies and whether they’re increasing.
● Paternal antigen testing or cell-free DNA (cffDNA) – These help determine whether your
baby has inherited the antigen your antibodies are targeting. Paternal testing checks if
the baby’s father carries the antigen, while cffDNA is a non-invasive blood test that may
show if the baby has it too.
● MCA Doppler ultrasounds – Starting around 18 to 20 weeks, this special ultrasound
measures blood flow in the baby’s brain to check for signs of anemia.
● Routine ultrasounds – To monitor growth, amniotic fluid levels, and overall wellbeing.
● Antenatal testing (starting at 32 weeks) – Usually includes twice-weekly non-stress tests
(NSTs) and ultrasounds called biophysical profiles (BPPs). NSTs track the baby’s heart
rate and movement, while BPPs check fluid, movement, tone, and practice breathing.
If your titer level reaches a critical level, your care plan should include a referral to a
maternal-fetal medicine (MFM) specialist for additional monitoring and support.
Questions to ask your OB
You want someone who is familiar with the condition, or who can refer you to a specialist who is.
Understanding your antibody levels and how they’re monitored is key to tracking risk.
Ask whether the baby may be at risk, and if cffDNA or paternal testing is an option.
This usually includes MCA Doppler ultrasounds to watch for signs of anemia.
If your titers reach a critical level, you will need to see a maternal-fetal medicine (MFM) specialist for MCA Doppler ultrasounds, which help check for early signs of anemia in your baby.
We recommend delivering at a hospital with a Level 3 or Level 4 NICU, where specialized teams are equipped to care for babies who may need advanced monitoring, treatment, or transfusions after birth.
Make sure there’s a pediatrician or neonatologist who understands HDFN and can follow up
closely.
It’s important to feel safe speaking up. A good care team will listen and take your concerns
seriously.
Get Involved with MAF
Your voice, time, and generosity can help save lives. Whether you donate, fundraise, share your story, or simply spread the word, every action helps us reach another family who may need support.
Making a Difference
Patient Stories
Thank you to the kind families who have shared their journey!
Candace’s Story
At 11 weeks pregnant, I was shocked to learn I had four red blood cell antibodies, despite having received Rhogam in past pregnancies. After eight transfusions, I delivered Caden at 37 weeks. He spent 19 days in the NICU and faced serious challenges, but today, he’s healthy and thriving. “Reaching out for help saved his life.”
Jessica’s Story
At 37 weeks with my fifth baby, my low anti-c titers seemed reassuring—until our newborn needed an emergency exchange transfusion within 24 hours. Later pregnancies were closely managed with MCA scans, early deliveries, and NICU plans. Some babies needed phototherapy or transfusions, but all are healthy today. “With proper monitoring and a team you trust… it makes all the difference.”
Hailey’s Story
During my first pregnancy, I was shocked to learn I had developed anti-D antibodies, despite no known cause. My second pregnancy was more carefully managed, and our daughter River, thankfully Rh-negative, was unaffected. I feel incredibly lucky—“The extra monitoring and worry are so insignificant in comparison to the years of happiness our iso baby has brought us.”